Clinical Trials
5 trialsNCT07504796 2026-04-21
ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab
NYU Langone Health
Phase 4 Recruiting
NCT07459543 2026-03-09
A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unresectable or Metastatic Melanoma Participants In India
Bristol-Myers Squibb
Phase 4 Not yet recruiting
NCT02626065 2025-09-15
PAIR
Hospices Civils de Lyon
Phase 4 Completed
NCT06116461 2024-04-22
NIVOPTIMIZE
Erasmus Medical Center
Phase 4 Unknown
NCT03313544 2023-04-21
Evolution of the Heart Function When Monitoring Immunotherapies Anti-cancerous Inhibiting PD-1
Assistance Publique Hopitaux De Marseille
Phase 4 Unknown